

MEDIA CONTACTS:

Erik Clausen or Kena Hudson

College Hill, Inc. for Amarantus Therapeutics, Inc.

415-230-5385

Erik.Clausen@CollegeHill.com or Kena.Hudson@CollegeHill.com

Amarantus Therapeutics Inc. Appoints Dr. Robert J. Zimmerman as Chief Development Officer

Company to Present at the C21 BioVentures Conference on Thursday, May 27, 2010 at 10:30AM PST

SUNNYVALE – May 24, 2010 – [Amarantus Therapeutics, Inc.](#), a privately-held biotechnology company developing first-in-class disease-modifying treatments that address the underlying cause of cell death, today announced the appointment of Robert J. Zimmerman, S.D., as a consulting Chief Development Officer. In his consulting role, he will help to oversee the development of Amarantus' lead candidate, AMRS001 for the treatment of several apoptosis-related disorders. Additionally, Martin D. Cleary, Chief Executive Officer of Amarantus, will present an update on Amarantus' activities at the C21 BioVentures Conference on Thursday, May 27, 2010 at 10:30AM PST at the Meritage Resort in Napa, California.

Dr. Zimmerman comes to Amarantus with over 25 years of management and drug development experience in both public and privately held companies with small molecules and protein drugs. During his career, he has led numerous development teams from discovery to marketing and has a successful product development record, contributing to the market approval of several drugs and the filing of multiple investigational new drug applications.

“Robert brings the necessary vision, leadership and understanding from his years dedicated to the development of new drugs to help advance our product pipeline of our innovative therapeutics,” stated Cleary. “His experience and demonstrated leadership will be of great benefit to Amarantus as we continue to further the Company’s first-in-class, disease modifying, MANF technology.”

Dr. Zimmerman commented, “I look forward to working with the Company and contributing to the forward momentum being built by Amarantus in pioneering new and improved treatments that address the underlying cause of apoptosis, which is associated with a wide range of diseases. Amarantus’ unique and proprietary PhenoGuard protein discovery engine offers compelling advantages by allowing for the rapid discovery of novel secreted human proteins with biological activity for specific indications. I am pleased to join the team at this exciting stage of the Company’s development and look forward to advancing AMRS001 through development.”

Prior to joining Amarantus, Dr. Zimmerman held management positions at Signature BioScience, Inc. Dr. Zimmerman also formerly served as the Vice President of Biotechnology Research at Bayer Corporation, where he was responsible for the management of all biotechnology research activities within the Pharmaceutical Division. Dr. Zimmerman received a

doctorate of science and a master's of science in physiology and radiobiology from the Harvard School of Public Health. He also received a master's of science in physiology from Ohio State University and earned a B.S. from Denison University.

About Amarantus Therapeutics, Inc.

Amarantus Therapeutics, Inc. is a privately-held biotechnology company developing first-in-class disease-modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases, including but not limited to, neurodegenerative and cardiovascular. The Company's most advanced drug candidate, AMRS001, is a growth factor indicated for the treatment of Parkinson's disease and Myocardial Infarction. Currently incubating at the Parkinson's Institute, Amarantus Therapeutics is seeking to raise a \$1 million investment as a bridge to a \$15 million Series A that it will use to advance its lead programs in Parkinson's and Myocardial Infarction into clinical development. www.amarantustherapeutics.com

###